Search results
- (-) Remove Research filter Research
Balancing risk to optimise reward
Oxford BioMedica is a leader in lentivirus based gene technology and ongoing manufacturing deals (CTL019 with Novartis) underpin the valuation.
Harnessing the CAR-T
Over the past year, Oxford BioMedica’s outlook has been transformed.
New non-dilutive funding to expand production
Oxford BioMedica has secured a $50m loan facility from Oberland Capital.